Pyxis Oncology falls as cash runway raises capital concerns
Revenue decline and limited funds into 2026 overshadow positive MICVO clinical data
Pyxis Oncology shares extended their decline on Tuesday as the biotechnology company reported deteriorating financials and revealed a cash runway that extends only into the fourth quarter of 2026, raising concerns about potential near-term capital raising needs. The stock, trading at $1.47, has fallen 73% from its 52-week high of $5.55 and currently sits below both its 50-day and 200-day moving averages.
The Cambridge, Massachusetts-based company reported full-year revenue of $13.9 million for 2025, representing a 13.7% decline from $16.1 million in the prior year. The revenue was primarily derived from a regulatory milestone related to the approval of suvemcitug in China and the sale of royalty rights for Enzeshu® to Simcere, highlighting the company's reliance on one-time gains rather than recurring commercial revenue.
Net loss widened to $79.6 million for the full year, with the company reporting a loss per share of $1.28. As of December 31, 2025, Pyxis held cash, cash equivalents, restricted cash, and short-term investments totaling $68.3 million. Management stated that this position should fund operations into the fourth quarter of 2026, a timeline that some analysts view as insufficient comfort given the typical development timelines for oncology assets.
Despite the financial challenges, Pyxis provided positive updates on its lead clinical program, micvotabart pelidotin (MICVO), an antibody-drug conjugate targeting solid tumors. In recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC), MICVO demonstrated a 46% confirmed objective response rate as monotherapy in second-line or later patients, with a disease control rate of 92%. In combination with Merck's Keytruda® (pembrolizumab), the therapy achieved a 71% confirmed ORR and 100% disease control rate.
The company has completed target enrollment in the Phase 1 monotherapy dose expansion study of MICVO for 2L+ R/M HNSCC, with updated data expected in mid-2026. Additionally, updated results from the combination study are anticipated in the second half of 2026. MICVO has received Fast Track Designation from the U.S. Food and Drug Administration for R/M HNSCC that has progressed after platinum-based chemotherapy and anti–PD-(L)1 therapy.
The clinical data has maintained a mixed analyst outlook, with a median price target of $7.00 representing a roughly 376% premium to the current share price. Analysts maintain a "Buy" or "Moderate Buy" consensus rating, reflecting confidence in MICVO's efficacy profile and favorable tolerability. However, short interest has increased 3.37% as investors weigh the funding challenges against the clinical potential.
Pyxis previously streamlined its operations in December 2024, halting clinical investments in PYX-106 to concentrate resources on MICVO. The strategic focus on a single clinical asset has raised the stakes for the upcoming data readouts, as any setbacks would leave the company with limited backup programs.
The coming months will be critical for Pyxis Oncology as it seeks to extend its cash runway while simultaneously delivering on the clinical milestones that investors have pinned their hopes on. With enrollment complete and key data reads on the horizon, the company's ability to navigate the funding gap while advancing MICVO through late-stage development will likely determine whether the stock can recover from its current depressed levels or face further dilution from potential equity offerings.